探讨阿托伐他汀治疗冠心病性心力衰竭的临床效果及对相关指标的影响

Investigation on the clinical effect of atorvastatin in the treatment of coronary heart disease with heart failure and its influence on related indicators

目的探讨阿托伐他汀治疗冠心病性心力衰竭临床效果及对相关指标的影响。方法 120例冠心病性心力衰竭患者,按照随机数字表法分为对照组和观察组,每组60例。对照组给予常规抗心衰药物治疗,观察组给予常规抗心衰药物联合阿托伐他汀治疗。比较两组患者的治疗效果、心力衰竭纠正时间、症状缓解时间、不良反应发生情况及治疗前后心功能情况[左室舒张末期内径、左室收缩末期内径、左室射血分数]、血浆N末端B型利钠肽原(NT-proBNP)情况。结果观察组治疗总有效率93.33%高于对照组的66.67%,差异有统计学意义(P<0.05)。治疗后观察组左室舒张末期内径、左室收缩末期内径、左室射血分数、血浆NT-proBNP情况均优于对照组,差异有统计学意义(P<0.05)。观察组心力衰竭纠正时间(11.11±1.02)d、症状缓解时间(8.13±0.01)d均短于对照组的(14.42±2.11)、(11.23±1.21)d,差异有统计学意义(P<0.05)。观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论常规抗心衰药物联合阿托伐他汀治疗冠心病性心力衰竭的疗效确切,可有效改善心功能情况、血浆NT-proBNP情况,用药安全,值得推广应用。

Objective To investigate the clinical effect of atorvastatin in the treatment of coronary heart disease with heart failure and its influence on related indicators.Methods A total of 120 coronary heart disease patients with heart failure were divided by random number table into control group and observation group,with 60 cases in each group.The control group was treated with routine anti-heart failure drugs,and the observation group was treated with routine anti-heart failure drugs combined with atorvastatin.Comparison were made on treatment effect,correction time of heart failure,remission time of symptoms,occurrence of adverse reactions and cardiac function before and after treatment[left ventricular end-diastolic diameter,left ventricular end-systolic diameter,left ventricular ejection fraction],plasma N-terminal pro-B-type natriuretic peptide(NT-proBNP)between the two groups.Results The observation group had higher total treatment effective rate as 93.33%than 66.67%in the control group,and the difference was statistically significant(P<0.05).After treatment,the observation group had better left ventricular end-diastolic diameter,left ventricular end-systolic diameter,left ventricular ejection fraction and plasma NT-proBNP than the control group,and the difference was statistically significant(P<0.05).The observation group had correction time of heart failure as(11.11±1.02)d,remission time of symptoms as(8.13±0.01)d,which were all shorter than(14.42±2.11)and(11.23±1.21)d in the control group,and their difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the observation group and control group(P>0.05).Conclusion Combination of routine anti-heart failure drugs and atorvastatin shows affirmative efficacy in treating coronary heart disease with heart failure,and it can effectively improve cardiac function and plasma NT-proBNP.It is safe for drug use and worthy of popularization and application.